Seite - 121 - in Cancer Nanotheranostics - What Have We Learnd So Far?

Clift et al. Theranosticnanoparticlesand thebloodstream subsequent cell interaction of polymer coated SPIONs in vitro. Nanoscale 5, 3723–3732. doi: 10.1039/c2nr33134a Hirsch, V., Kinnear, C., Rodriquez-Lorenzo, L., Monnier, C. A., Rothen-Rutishauser, B., Balog, S., et al. (2014). In vitro dosimetry of agglomer- ates.Nanoscale 7, 7325–7331. doi: 10.1039/c4nr0 0460d ISO. (2008). International Organization for Standardization (ISO) Technical Specification (ISO/TS) 27687:2008; Nanotechnologies – Terminology and Definitions for Nano-Objects – anoparticle, Nanofibre and Nanoplate; First published2008-08-15. Kempe, M., Kempe, H., Snowball, I., Wallen, R., Arza, C. R., Gotberg, M., et al. (2010). The use of magnetite nanoparticles for implant- assistedmagnetic drug targeting in thrombolytic therapy. Biomaterials 31, 9499–9510. doi: 10.1016/j.biomaterials.2010.07.107 Kim, H., Lee, S., and Chen, X. (2013). Nanotheranostics for personalized medicine. Expert Rev. Mol. Diagn. 13, 257–269. doi: 10.1586/erm.13.15 Kreyling, W. G., Semmler-Behnke, M., Takenaka, S., and Möller, W. (2012). Differences in the biokinetics of inhaled nano- versus micrometer- sized particles.Acc. Chem. Res. 46, 714–722. doi: 10.1021/ar300043r Krol, S.,Macrez, R., Docagne, F., Defer, G., Laurent, S., Rahman,M., et al. (2013). Therapeutic bene- fits fromnanoparticles: the potential significance ofnanoscience indiseaseswithcompromise to the blood brain barrier.Chem. Rev. 113, 1877–1903. doi:10.1021/cr200472g Li, L., Wan, H., Ong, Z. Y., Xu, K., Ee, P. L. R., Zheng, S., et al. (2010). Polymer- and lipid- based nanoparticle therapeutics for the treat- mentof liverdiseases.Nanotoday 5, 296–312. doi: 10.1016/j.nantod.2010.06.007 Liu, G., Garrett, M. R., Men, P., Zhu, X., Perry, G., and Smith, M. A. (2005). Nanoparticle and other metal chelation therapeutics in Alzheimer disease. Biochim. Biophys. Acta Mol. Basis Dis. 1741, 246–252. doi: 10.1016/j.bbadis.2005. 06.006 Liu, Y., Tan, J., Thomas, A., Ou-Yang, D., and Muzykantov, V. R. (2012). The shape of things to come: importance of design in nanotechnol- ogy fordrugdelivery.Ther.Deliv. 3, 181–194.doi: 10.4155/tde.11.156 Lynch, I., Dawson, K. A., and Linse, S. (2006). Detecting cryptic epitopes created by nanoparticles. Sci. STKE 2006:pe14. doi: 10.1126/stke.3272006pe14 Mamalis,A.G. (2007).Recent advances innanotech- nology. J. Mater. Process Tech. 181, 52–58. doi: 10.1016/j.jmatprotec.2006.03.052 McMillan, J., Batrakova, E., and Gendelman, H. E. (2014). Cell delivery of therapeutic nanoparticles. Prog Mol. Biol. Transl. Sci. 104, 563–601. doi: 10.1016/B978-0-12-416020-0. 00014-0 Melancon, M. P., Stafford, R. J., and Lia, C. (2012). Challenges to effective cancer nanother- anostics. J. Control Release 164, 177–182. doi: 10.1016/j.jconrel.2012.07.045 Muthu,M. S., Leong, D. T.,Mei, L., and Feng, S.-S. (2014). Nanotheranostics – Application and fur- ther development of nanomedicine strategies for advanced Theranostics. Theranostics 4, 660–677. doi:10.7150/thno.8698 Najafi, S., Pazhouhnia, Z., Ahmadi, O., Berenjian, A., and Jafarizadeh-Malmiri, H. (2014). Chitosan nanoparticles andtheir applications indrugdeliv- ery:areview.Curr.Res.DrugDiscov. 1,17–25.doi: 10.3844/crddsp.2014.17.25 Nichols, J. W., and Bae, Y. H. (2012). Odyssey of a cancer nanoparticle: from injection site to site of action. Nanotoday 7, 606–618. doi: 10.1016/j.nantod.2012.10.010 Nicolaides,N.C.,O’Shannessy,D. J., Albone, E., and Grasso, L. (2014). Co-development of diagnostic vectors to support targeted therapies and thera- nostics: essential tools inpersonalizedcancer ther- apy. Front. Oncol. 4:141. doi: 10.3389/fonc.2014. 00141 Niemirowicz, K., Markiewicz, K. H., Wilczewska, A. Z., and Car, H. (2012). Magnetic nanopar- ticles as new diagnostic tools in medicine. Adv. Med. Sci. 57, 196–207. doi: 10.2478/v10039-012- 0031-9 Petros, R.A., andDeSimone, J.M. (2010). Strategies in the design of nanoparticles for therapeutic applications.Nat. Rev. Drug Discov. 9, 615–627. doi:10.1038/nrd2591 Pison, U., Welte, T., Giersig, M., and Groneberg, D. A. (2006). Nanomedicine for respiratory dis- eases. Eur. J. Pharmacol. 533, 341–350. doi: 10.1016/j.ejphar.2005.12.068 Rothen-Rutishauser, B. M., Schürch, S., Haenni, B., Kapp, N., and Gehr, P. (2006). Interaction of fine particles and nanoparticles with red blood cells visualized with advanced microscopic tech- niques. Environ. Sci. Technol. 40, 4353–4359. doi: 10.1021/es0522635 Thon, J. N., Mazutis, L., Wu, S., Sylman, J. L., Ehrlicher,A.,Machlus,K.R., et al. (2014).Platelet bioreactor-on-a-chip.Blood. 124, 1857–1867. doi: 10.1182/blood-2014-05-574913 Xie, J., Lee, S., and Chen, X. (2011). Nanoparticle- basedtheranosticagents.Adv.Drug.Deliv.Rev.62, 1064–1079.doi:10.1016/j.addr.2010.07.009 Ye, L., Yong, K.-T., Liu, L., Roy, I., Hu, R., Zhu, J., etal. (2012).Apilotstudyinnon-humanprimates shows no adverse response to intravenous injec- tionof quantumdots.Nat.Nanotech. 7, 453–458. doi:10.1038/nnano.2012.74 Conflict of Interest Statement:The authors declare that the researchwasconducted in theabsenceof any commercial or financial relationships that could be construedasapotential conflictof interest. Received: 22October 2014; accepted: 21 January 2015; publishedonline:10February2015. Citation: Clift MJD, Dechézelles J-F, Rothen- Rutishauser B and Petri-Fink A (2015) A biological perspective toward the interaction of theranostic nanoparticles with the bloodstream – what needs to be considered? Front. Chem. 3:7. doi: 10.3389/fchem. 2015.00007 This article was submitted to Chemical Engineering, a sectionof the journalFrontiers inChemistry. Copyright © 2015 Clift, Dechézelles, Rothen- Rutishauser and Petri-Fink. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CCBY). The use, dis- tribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited andthat theoriginalpublication in this journal is cited, in accordancewith accepted academic practice.Nouse, distributionorreproductionispermittedwhichdoesnot complywith these terms. Frontiers inChemistry | ChemicalEngineering February2015 |Volume3 |Article7 | 121